CRISPR Therapeutics (CRSP) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic progress and pipeline updates

• Four main franchises—hemoglobinopathies, in vivo gene editing, CAR-T, and diabetes—showed significant advancements, with commercial and clinical milestones across each.

• Casgevy achieved global regulatory approvals for SCD and TDT, launched in 10 countries, exceeded $100 million in revenue, and expanded into pediatric populations with strong pivotal data.

• In vivo gene editing platforms advanced, with CTX310 showing ~50% LDL and ~55% triglyceride reductions and CTX320/321 targeting Lp(a) with up to 90% reduction potential.

• CAR-T programs, including CTX112 and zugo-cel, demonstrated high response rates in oncology and autoimmune diseases, with ongoing expansion into new indications and combination strategies.

• Type 1 diabetes programs showed proof-of-concept for durable, stealth islet cell therapies, with CTX213 advancing as a best-in-class candidate.

Clinical and regulatory outlook

• Multiple phase 1 assets (CTX310, CTX611, CTX112) are progressing, with pivotal trial designs and regulatory discussions underway for next steps.

• Preclinical assets like A1AT and AGT are poised to enter the clinic, with A1AT showing best-in-class preclinical efficacy and AGT offering dramatic blood pressure reduction.

• Regulatory agencies, especially the FDA, are increasingly supportive of gene editing, with expectations for streamlined pivotal trials and earlier intervention in disease courses.

• Strategic decisions on asset development versus partnering are anticipated, with growing pharma interest in cell and gene therapies for both rare and common diseases.

• 2026 is positioned as a pivotal year, with key data readouts, regulatory clarity, and expansion into new indications expected for CASGEVY, in vivo HSC, CTX310, CTX611, CTX340, CTX460, Lp(a), zugo-cel, and in vivo CAR-T programs.

Market access, innovation, and societal impact

• Cost-reduction strategies include transitioning to in vivo editing and allogeneic CAR-Ts, aiming for one-time interventions that are more affordable and scalable.

• Pharmacoeconomic benefits are emphasized, with cardiovascular therapies potentially priced below $100,000 and allogeneic CAR-Ts under $10,000 per patient.

• Tailored therapies are being developed to address genetic and ethnic diversity, leveraging sequencing data for more personalized approaches.

• AI is increasingly used in preclinical research for protein and mRNA design, with future potential to enhance clinical trial efficiency.

• The immune reset concept in autoimmune diseases is expected to transform treatment paradigms, with ongoing expansion into additional indications.